Check-Cap to merge with MBody AI in embodied AI workforce push
Investing.com - Piper Sandler initiated coverage on 10X Genomics (NASDAQ:TXG) with a Neutral rating and a $15.00 price target on Thursday. According to InvestingPro data, the stock currently trades at $12.59, with analyst targets ranging from $13 to $17. The company’s current market capitalization stands at $1.57 billion.
The research firm acknowledged 10X Genomics has the leading offering in the single cell market with the largest install base and technological advantages compared to competitors. InvestingPro analysis shows the company maintains strong financial health with a current ratio of 5.84 and more cash than debt on its balance sheet.
Piper Sandler also noted the company has the largest following in spatial and in situ technologies, a market segment they believe has potential comparable to Next Generation Sequencing (NGS).
Despite these strengths, the firm cited ongoing price compression in the single cell market as a concern for the company’s near-term performance.
The research firm recommended investors wait for 10X Genomics to navigate the current macroeconomic environment before considering investment, noting that the spatial market may take several years to fully develop.
In other recent news, 10X Genomics Inc . reported a notable earnings surprise for the second quarter of 2025. The company achieved an earnings per share (EPS) of $0.28, surpassing the forecasted -$0.37. Revenue for the quarter reached $173 million, exceeding expectations by 24.03%. These results highlight a strong financial performance for the period. Despite the positive earnings and revenue figures, the company’s stock experienced a decline in after-hours trading. Investors and analysts are closely monitoring these developments. The earnings beat and revenue growth are significant for stakeholders. Analysts from various firms may provide further insights into these results. These recent developments are essential for those following 10X Genomics Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.